38 / 53
Patients
without
brain mets at baseline
1.0
0.8
0.6
0.4
0.2
0
Ceritinib (n=130)
Chemotherapy (n=125)
HR=0.48 (0.33–0.69)
0
36
12
3
24
33
30
6
21
15
9
18
27
26.3
8.3
Time (months)
PFS estimate
1.0
0.8
0.6
0.4
0.2
0
Ceritinib (n=59)
Chemotherapy (n=62)
HR=0.70 (0.44–1.12)
0
36
12
27
3
9
21
33
Time (months)
PFS estimate
24
18
6
15
30
10.7
6.7
Patients
with
brain mets at baseline
Soria, et al. Lancet 2017
ASCEND-4: PFS in patients with and without SNC
mets